Wellend Health

Women's HealthEducation Center

Search

International research partnership with GTx, Inc.

17 June 2016 | By Wellend

Wellend, in partnership with the private Australian research organisation Havah Pty Ltd, is pleased to announce that it has entered into a research partnership with NASDAQ listed GTx, Inc. in order to undertake three concurrent Phase II clinical trials in the utilisation of Selective Androgen Receptor Modulators in breast cancer prevention, through targeting mammographic breast density, and breast cancer treatment.

The Wellend clinic at Attunga House will be involved in a Phase II single-centre study investigating the efficacy and safety of GTx-024 and anastrozole in peri-menopausal women with high mammographic breast density. In addition, Wellend will run a Phase II open label, multi-center, multinational, randomised, parallel design study investigating the efficacy and safety of GTx-024 on metastatic or locally advanced ER+/AR+ breast cancer in postmenopausal women. A Phase II open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR+ TNBC) will also be conducted over the coming two years.

GTx is dedicated to developing novel targeted hormonal therapies to provide better medicines for patients. GTx focuses on the development of small molecules that selectively modulate the effects of certain hormones produced by the body. GTx is developing selective androgen receptor modulators, also referred to as SARMs, to potentially treat a number of serious diseases, including breast cancer, stress urinary incontinence and Duchenne muscular dystrophy. In addition, GTx has compounds that selectively target oestrogen receptors in preclinical development for fibrotic conditions, such as Idiopathic Pulmonary Fibrosis (IPF). To further explore treatments targeting diseases caused by abnormal androgen receptor signalling, GTx has a preclinical program to develop selective androgen receptor degraders (SARDs) for prostate cancer patients who no longer respond to androgen deprivation therapy.